The Myofascial Pain Syndrome is typically characterized by the presence of trigger points that are subject to treatment through the injections of small doses of the Botulinum toxin type A (BTX-A). These produce prolonged muscle relaxation and can be easily targeted at the affected muscles.
A vast number of research reports advocate the use of BTX-A injections in the treatment of the Myofascial Pain Syndrome and Fibromyalgia.
A study was conducted by the Pain Evaluation & Treatment Centre in Tulsa for the purpose. 70 percent of patients with MPS in the back and extremities who received the BTX-A injections over a two year period reported a remarkable pain relief for 2.5 to 3.6 months. The patients were even able to support a therapeutic exercise regimen along with.